CytomX Therapeutics (CTMX) Non-Current Deferred Tax Liability (2014 - 2018)
CytomX Therapeutics' (CTMX) quarterly Non-Current Deferred Tax Liability came in at $1.1 million in Q4 2018, up 118.65% on a QoQ basis from $520000.0 in Q3 2017.
CytomX Therapeutics (CTMX) Non-Current Deferred Tax Liability (2014 - 2018) Analysis & Trends
CytomX Therapeutics (CTMX) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $1.1 million in Q4 2018.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.1 million (changed N/A YoY) and the FY2018 annual result came in at $1.1 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability rose to $1.1 million in Q4 2018, from $520000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q4 2018 to a low of $499000.0 in Q4 2014.
- A 5-year average of $570181.8 and a median of $513000.0 in 2016 frame the typical range for Non-Current Deferred Tax Liability.
- The widest YoY moves for Non-Current Deferred Tax Liability: up 5.07% in 2017, down 0.78% in 2017.
- Tracing CTMX's Non-Current Deferred Tax Liability over 5 years: stood at $499000.0 in 2014, then gained by 1.6% to $507000.0 in 2015, then climbed by 1.18% to $513000.0 in 2016, then increased by 1.36% to $520000.0 in 2017, then surged by 118.65% to $1.1 million in 2018.
- The last three Non-Current Deferred Tax Liability figures came in at $1.1 million (Q4 2018), $520000.0 (Q3 2017), and $539000.0 (Q2 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 1.14 Mn |
| Dec 31, 2018 | 1.14 Mn |
| Sep 30, 2017 | 520,000.00 |
| Sep 30, 2017 | 520,000.00 |
| Jun 30, 2017 | 539,000.00 |
| Jun 30, 2017 | 539,000.00 |
| Mar 31, 2017 | 514,000.00 |
| Mar 31, 2017 | 514,000.00 |
| Dec 31, 2016 | 513,000.00 |
| Dec 31, 2016 | 513,000.00 |
| Sep 30, 2016 | 513,000.00 |
| Sep 30, 2016 | 513,000.00 |
| Jun 30, 2016 | 513,000.00 |
| Jun 30, 2016 | 513,000.00 |
| Mar 31, 2016 | 510,000.00 |
| Mar 31, 2016 | 510,000.00 |
| Dec 31, 2015 | 507,000.00 |
| Dec 31, 2015 | 507,000.00 |
| Sep 30, 2015 | 507,000.00 |
| Sep 30, 2015 | 507,000.00 |